论文部分内容阅读
目的评价替吉奥单药三线治疗转移性乳腺癌的有效性与安全性。方法 49例转移性女性乳腺癌患者,既往接受过针对转移性乳腺癌的细胞毒化疗方案2个,予替吉奥胶囊:40 mg/m2/次,2次/d,早晚餐后30 min内口服,1~28 d,随后休息14 d,每6周为一周期,每2个周期复查电子计算机断层扫描(computed tomography,CT)或核磁共振(MRI)按RECIST 1.1标准评价近期疗效,每周期均按CTCAE4.0评价不良反应。结果 1例患者因面部严重皮疹未能完成1周期治疗出组,48例可评价患者中完全缓解0.00%(0/48),部分缓解20.83%(10/48),疾病稳定50.00%(24/48),疾病进展29.17%(14/48),客观反应率20.83%(10/48),疾病控制率70.83%(34/48),中位无进展生存期5.90月(95%CI:5.03~6.77个月)。骨髓抑制、腹泻是剂量限制性毒性。结论替吉奥胶囊单药三线治疗转移性乳腺癌,疾病控制率较高,不良反应能够耐受,且服药方便,值得临床进一步探索。
Objective To evaluate the efficacy and safety of Tretinoin as a single agent in the treatment of metastatic breast cancer. Methods A total of 49 metastatic female breast cancer patients were previously treated with 2 cytotoxic chemotherapy regimens for metastatic breast cancer. They were given 40 mg / m 2 / d twice daily for 30 min after breakfast and after meal Oral, 1- 28 d, then rest 14 d, every 6 weeks for a cycle, review every 2 cycles of computed tomography (CT) or MRI according to RECIST 1.1 standard assessment of short-term efficacy, each cycle According to CTCAE4.0 evaluation of adverse reactions. Results One patient was treated with one cycle because of serious rashes. The complete remission rate was 0.00% (0/48) in 48 evaluable patients, 20.83% (10/48) in partial remission, and 50.00% in stable disease (24 / 48), disease progression was 29.17% (14/48), objective response rate was 20.83% (10/48), disease control rate was 70.83% (34/48), median progression-free survival was 5.9 months (95% CI: 5.03 ~ 6.77 months). Myelosuppression and diarrhea are dose-limiting toxicities. Conclusion Treating cancer metastatic breast cancer with three-line treatment of GeJiao capsules, the disease control rate is high, the adverse reaction can be tolerated, and the medication is convenient, so it is worth further exploration in clinic.